A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Latest Information Update: 10 Dec 2024
At a glance
- Drugs Tirzepatide (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURPASS-EARLY
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 Dec 2024 Planned End Date changed from 29 Nov 2027 to 1 Nov 2027.
- 06 Dec 2024 Planned primary completion date changed from 30 Oct 2025 to 1 Oct 2025.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.